Ipsen Past Earnings Performance

Past criteria checks 5/6

Ipsen has been growing earnings at an average annual rate of 23.9%, while the Pharmaceuticals industry saw earnings declining at 2.4% annually. Revenues have been growing at an average rate of 6.2% per year. Ipsen's return on equity is 16.5%, and it has net margins of 19.3%.

Key information

23.9%

Earnings growth rate

24.0%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate6.2%
Return on equity16.5%
Net Margin19.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ipsen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0MH6 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243,4356641,157653
31 Mar 243,3716411,146636
31 Dec 233,3066171,135619
30 Jun 233,2824061,105528
31 Mar 233,2195001,072487
31 Dec 223,1565931,039445
30 Sep 223,0536561,007436
30 Jun 222,950719975427
31 Mar 222,849675946425
31 Dec 212,749631916424
30 Sep 212,712626923422
30 Jun 212,676622931420
31 Mar 212,681585951413
31 Dec 202,686548972406
30 Sep 202,697249986404
30 Jun 202,707-501,000403
31 Mar 202,700-531,010396
31 Dec 192,693-551,021389
30 Sep 192,6051761,003363
30 Jun 192,516406986337
31 Mar 192,432397970319
31 Dec 182,348388954302
30 Sep 182,258365931292
30 Jun 182,167343909281
31 Mar 182,090307883274
31 Dec 172,012270858266
30 Sep 171,923243821264
30 Jun 171,834217785262
31 Mar 171,753221752247
31 Dec 161,671226719231
30 Sep 161,623229703214
30 Jun 161,575233687196
31 Mar 161,548211676194
31 Dec 151,520189666193
30 Sep 151,468165651192
30 Jun 151,416140636191
31 Mar 151,374147606189
31 Dec 141,332154577187
30 Sep 141,310155557190
30 Jun 141,287156537193
31 Mar 141,284149543194
31 Dec 131,282142549196

Quality Earnings: 0MH6 has high quality earnings.

Growing Profit Margin: 0MH6's current net profit margins (19.3%) are higher than last year (12.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0MH6's earnings have grown significantly by 23.9% per year over the past 5 years.

Accelerating Growth: 0MH6's earnings growth over the past year (63.4%) exceeds its 5-year average (23.9% per year).

Earnings vs Industry: 0MH6 earnings growth over the past year (63.4%) exceeded the Pharmaceuticals industry 4.5%.


Return on Equity

High ROE: 0MH6's Return on Equity (16.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies